Dermisonics, Inc. to Present at Diabetes Technology Meeting WEST CONSHOHOCKEN, Pa., Oct. 28 /PRNewswire-FirstCall/ -- Dermisonics, Inc. (OTC:DMSI) (BULLETIN BOARD: DMSI) has been invited to present a scientific paper on its groundbreaking transdermal insulin delivery technology at the fourth annual Diabetes Technology Meeting to be held on October 28th through October 30, 2004 in Philadelphia, PA. The Diabetes Technology Meeting is a forum composed of healthcare professionals and scientists dedicated to disseminating information about advances in all realms of diabetes care including glucose control, new drug delivery methods, and emerging treatments. The meeting will assemble diabetes technology developers and users, including physicians, nurses, engineers, clinical chemists and diabetes educators for the purpose of furthering the cause of enhancing treatment of both Type I and Type II diabetes. Last year the meeting was attended by over 625 participants from 24 nations worldwide who were able to share a unique opportunity for exchange of information in both formal and informal settings. More information on this forum is available at http://www.diabetestechnology.org/. Ram Roy, Ph.D., Chief Scientific Officer of Dermisonics, the primary developer of the chemistry behind the Company's transdermal patch dubbed the "U-Strip," will present a scientific paper on the technology and its potential efficacy entitled Ultrasound-Mediated Transdermal Delivery. The paper will discuss the advantages of transdermal delivery over injection, inhalation, and oral delivery and will delineate the advances by Dermisonics in this field. Dr. Roy will describe utilizing ultrasound as a delivery enhancement method, and the effects of ultrasound on insulin stability as well as the results of human pilot trials conducted to assess the technology. Dermisonics' CEO Bruce Haglund commented, "I am pleased that the scientific community has recognized the value of our technological innovations in insulin delivery and chosen to demonstrate that recognition by extending an invitation to present at the Diabetes Technology Meeting. I feel confident that this is a strong initial step to introducing our science to diabetes healthcare professionals." About Dermisonics Dermisonics Inc. is a medical device company that is focused on the ongoing development, testing and eventual commercialization of a transdermal patch that has been designed to facilitate the efficient and needle-free delivery of heavy molecular drugs into the system. The U-Strip is a Drug Delivery System incorporating a transdermal patch in combination with microelectronics and ultrasonic technology. Tests have shown that this system facilitates the transdermal delivery of insulin as well as potentially at least 175 other existing drugs that at present cannot be effectively delivered through the pores of the skin using conventionally available transdermal technology due to their large molecular size. North American Investor Relations Contact: John Robinson 866-559-1333 Forward-Looking Statements A number of statements contained in this press release are forward-looking statements that are made pursuant to the Safe Harbour provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, many of which are beyond the control of the management of Dermisonics, including but not limited to: competitive market conditions, successful integration of acquisitions, reliance on key markets, suppliers and products, currency fluctuations, dependence on key personnel and trade restrictions, each of which may be impacted, among other things, by economic, competitive or regulatory conditions as well as the ability to secure additional sources of financing. Forward-looking statements by their nature involve substantial risks and uncertainties. Actual results achieved by Dermisonics may differ materially depending on many factors, including those described above. DATASOURCE: Dermisonics, Inc. CONTACT: John Robinson, North American Investor Relations, +1-866-559-1333, or , for Dermisonics, Inc. Web site: http://www.diabetestechnology.org/

Copyright